TNFRSF14 and B-cell chronic lymphocytic leukemia: They first revealed the inhibitory effect of BTLA/HVEM on NK cell-mediated immune responses and the influence on patients’ prognosis in this disease, suggesting that the BTLA/HVEM axis may be a potential therapeutic target for CLL [54].